The Dow posted a modest loss on Friday.

道指週五出現小幅下跌。

While they were minor gains for the S and P 500 the NASDAQ longer term, Wall Street snapped a three week winning streak.

雖然他們是小幅上漲的S和P 500納斯達克長期，華爾街打破了三個星期的連勝。

Greg Hahn, chief investment officer at With Capital Management.

With Capital Management的首席投資官Greg Hahn。

We think we're in a holding pattern.

我們認為我們正處於一個持有模式。

We think we have to see what happens with Stimulus Right now.

我們認為，我們必須看看現在的刺激計劃會發生什麼。

I think portfolio managers air looking at getting portfolios in shape heading into the end of the year.

我認為投資組合經理們在進入年底的時候，會考慮讓投資組合進入狀態。

So we're gonna start to see tax loss, harvesting some positional trading.

所以我們要開始看到稅收損失，收穫一些倉位交易。

But in terms of of altering the portfolio with respect to stock selection right now, I think we just have to wait and see what stimulus looks like.

但就現在改變投資組合的選股而言，我認為我們只需要等待，看看刺激政策是怎樣的。

It's been a good it's been a good three weeks.

這是一個很好的 這是一個很好的三個星期。

Though there were a number of earnings duds, American Express missed third quarter profit estimates.

雖然有不少財報啞火，但美國運通第三季度利潤未達預期。

Its cardholders, who tend to skew more affluent, spent roughly 20% less over the past three months.

其持卡人往往更偏向於富裕，在過去的三個月裡，他們的消費大約減少了20%。

Profits also took a hit from the $665 million Amex set aside to cover card spending than might go unpaid.

美國運通公司預留的6.65億美元用於支付比可能未支付的卡消費，利潤也受到了衝擊。

Shares of chipmaker Intel tumbled 10.5%.

芯片製造商英特爾的股價下跌了10.5%。

Wall Street frowned upon a quarterly sales mix that bent MAWR towards less profitable chips for cheaper laptops and slower government data center spending.

華爾街對季度銷售組合皺了眉頭，這使MAWR轉向利潤較低的芯片，用於更便宜的筆記本電腦和政府數據中心支出放緩。

But in three bright spots, Gilead Sciences rose after its anti viral drug Rendez Affair became the first and Onley drug to get US approval for treating patients hospitalized with Cove.

但在三個亮點中，吉利德科學公司在其抗病毒藥物Rendez Affair成為第一個和Onley藥物獲得美國準許，用於治療住院的Cove患者後，吉利德科學公司上漲。

In 1930 FDA gave AstraZeneca the green light to restart late stage clinical trials for experimental covert 19 vaccine.

1930年FDA給阿斯利康開了綠燈，重啟實驗性隱性19號疫苗的後期臨床試驗。

U.

U.

S trials were halted for more than a month after a report of a serious neurological illness in a British participant.

S試驗停止了一個多月，因為有報道稱一名英國參與者患有嚴重的神經疾病。

And Johnson and Johnson says it has been cleared to resume its covert 19 vaccine trials after it was briefly halted due to what it called a serious medical event.

而強生公司表示，在因所謂的嚴重醫療事件而短暫停止後，它已被準許恢復其祕密的19種疫苗試驗。